Evidence map›Paper›PMID 38075802›Full record

ArticleACS omega2023

Analysis, Modeling, and Target-Specific Predictions of Linear Peptides Inhibiting Virus Entry.

Boris Vishnepolsky, Maya Grigolava, Andrei Gabrielian, Alex Rosenthal, Darrell Hurt, Michael Tartakovsky, Malak Pirtskhalava

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Boris VishnepolskyIvane Beritashvili Center of Experimental Biomedicine, Tbilisi 0160, Georgia.ORCID https://orcid.org/0000-0001-5770-9481
Maya GrigolavaIvane Beritashvili Center of Experimental Biomedicine, Tbilisi 0160, Georgia.
Andrei GabrielianOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-6612, United States.
Alex RosenthalOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-6612, United States.
Darrell HurtOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-6612, United States.
Michael TartakovskyOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-6612, United States.
Malak PirtskhalavaIvane Beritashvili Center of Experimental Biomedicine, Tbilisi 0160, Georgia.
National Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiviral peptides (AVPs) are bioactive peptides that exhibit the inhibitory activity against viruses through a range of mechanisms. Virus entry inhibitory peptides (VEIPs) make up a specific class of AVPs that can prevent envelope viruses from entering cells. With the growing number of experimentally verified VEIPs, there is an opportunity to use machine learning to predict peptides that inhibit the virus entry. In this paper, we have developed the first target-specific prediction model for the identification of new VEIPs using, along with the peptide sequence characteristics, the attributes of the envelope proteins of the target virus, which overcomes the problem of insufficient data for particular viral strains and improves the predictive ability. The model's performance was evaluated through 10 repeats of 10-fold cross-validation on the training data set, and the results indicate that it can predict VEIPs with 87.33% accuracy and Matthews correlation coefficient (MCC) value of 0.76. The model also performs well on an independent test set with 90.91% accuracy and MCC of 0.81. We have also developed an automatic computational tool that predicts VEIPs, which is freely available at https://dbaasp.org/tools?page=linear-amp-prediction.

Identifiers

PMID38075802
PMCPMC10701718
OpenAlexW4388913112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.